The whole story, in order
Everything below is already built and live. Present the 11-slide deck for the simple version, or open each surface in sequence for the detail.
11 slides · arrow keys to advance · the simplest version of the whole story
Three demand pools — post-surgical, chronic MSK, chronic wounds — each with a live, indexed, converting surface. This is the distribution SofPulse doesn't have today.
The science behind tPEMFThe science is done — FDA-cleared, 17 years of evidence, 18 patents. The only thing between SofPulse and revenue is a channel. We install one — and share the risk: wholesale margin, milestone-vested equity, a slim fixed floor. ROI ~4.25× on the floor alone.
Clinical evidence baseWe're not a vendor — we're your exclusive DTC channel, equity-aligned. Three AKS-clean layers: take-title wholesale distribution, milestone-vested equity, and a fixed-fee floor ($5K/mo + $50/unit) for the federal lines. Full architecture, fees, compliance, and risk register inside.
AKS compliance deep diveThe two decisions Linda flagged, each with a recommendation: how to price the prescription fee, and which accreditations to pursue in what order.
HSA & LMN mechanicsThe relationship is qualified, the architecture is documented, and every surface you just saw is already in production. Both options are fixed-fee, FMV, AKS-clean. Day 0 is whenever we countersign.
Review the engagement & termsConfidential. Prepared for the SofPulse, Inc. team. Every linked surface is live but not indexed and not for distribution.